Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...3738394041424344454647...208209»
  • ||||||||||  Itari (linperlisib) / Shanghai YingLi Pharma
    DLBCL-ASSOCIATED PIM1 MUTATION DRIVES ANXA2 RELOCATION ON THE MEMBRANE AND PROMOTES LYMPHOMAGENESIS () -  May 4, 2025 - Abstract #ICML2025ICML_179;    
    Keyword: molecular targeted therapies Taken together, these findings not only shed light on an innovative regulatory mechanism for how PIM1L184F mutation contributes to the pathogenesis of DLBCL but also provide a potential therapeutic strategy for effectively managing DLBCL patients harboring PIM1L184F mutation.
  • ||||||||||  cisplatin / Generic mfg., AiRuiKa (camrelizumab) / HLB Bio Group, albumin-bound paclitaxel / Generic mfg.
    Journal:  Case Report: Exploring delayed hyperprogressive disease: a case study of post-immunotherapy in lung cancer. (Pubmed Central) -  May 2, 2025   
    This report is the first to present HPD after 5 months of immunotherapy, marking the longest recorded occurrence of this phenomenon. This particular case of post-immunotherapy HPD achieved satisfactory results through targeted segment arterial chemoembolization, offering a potential approach for managing this side effect.
  • ||||||||||  Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
    Enrollment change, Trial termination:  Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL (clinicaltrials.gov) -  Apr 30, 2025   
    P4,  N=39, Terminated, 
    However, vigilant monitoring of immune-mediated adverse events and infusion reactions remains critical in clinical practice. N=238 --> 39 | Recruiting --> Terminated; terminated
  • ||||||||||  ribupatide injection (HRS9531 injection) / Kailera Therapeutics
    Trial completion:  Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes (clinicaltrials.gov) -  Apr 30, 2025   
    P2,  N=249, Completed, 
    N=238 --> 39 | Recruiting --> Terminated; terminated Active, not recruiting --> Completed
  • ||||||||||  ribupatide injection (HRS9531 injection) / Kailera Therapeutics
    Trial completion, Trial primary completion date:  Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects (clinicaltrials.gov) -  Apr 30, 2025   
    P2,  N=199, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Apr 2024 --> Sep 2024
  • ||||||||||  HRS-5965 / Jiangsu Hengrui Pharma
    Enrollment closed:  A Trial of HRS-5965 Tablets in Primary IgA Nephropathy (clinicaltrials.gov) -  Apr 30, 2025   
    P2,  N=123, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Apr 2024 --> Sep 2024 Recruiting --> Active, not recruiting
  • ||||||||||  Oncorine (recombinant human adenovirus type 5) / Mergen Ltd., AiRuiKa (camrelizumab) / HLB Bio Group
    Journal, PD(L)-1 Biomarker, IO biomarker:  Oncolytic adenovirus H101 enhances the anti-tumor effects of PD-1 blockade via CD47 downregulation in tumor cells. (Pubmed Central) -  Apr 29, 2025   
    To investigate the anti-tumor effects of an E1B55KD-deleted oncolytic adenovirus, H101, in combination with a humanized anti-PD-1 (Programmed cell death protein 1) monoclonal antibody, Camrelizumab...These results suggested that H101 may act synergistically to enhance the therapeutic efficacy of PD-1 blockade in cancer via suppressing CD47 signaling, which may promote macrophages to phagocytose tumor cells and activate CD8+ T cells. The combination of H101 with PD-1 blockade exhibits potential as a novel strategy for the treatment of cancer.
  • ||||||||||  Journal, Checkpoint inhibition, Real-world evidence, PD(L)-1 Biomarker, IO biomarker:  Immune checkpoint inhibitors plus chemotherapy in the first-line treatment of young unresectable gastric cancer patients: a multicentre real-world study. (Pubmed Central) -  Apr 28, 2025   
    After screening, 134 patients were included for analysis: 63 received dual chemotherapy (mFOLFOX6, XELOX, SOX and two-drug containing paclitaxel), 32 PD-1 inhibitors plus dual chemotherapy (mFOLFOX6, XELOX, SOX and two-drug containing paclitaxel), and 39 triple regimens (two-drug chemotherapy combined with apatinib or trastuzumab, or triple chemotherapy based on platinum, fluorouracil and paclitaxel)...Young patients with GC have unique clinical characteristics and are not sensitive to immunotherapy. Triple regimens, especially intraperitoneal infusion of paclitaxel followed by intravenous paclitaxel combined with S-1 and apatinib oral therapy, deserve to be studied as first-line therapies.
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Pharma
    Review, Journal:  Advancing Nuclear Medicine through Discovery, Invention, and Innovation - Contribution of a Physicist and Scientist (Vikram Sarabhai Memorial Oration-2023). (Pubmed Central) -  Apr 28, 2025   
    Bendit Casin invented the rectilinear scanner, a pioneering imaging device, while Hal Anger developed the gamma camera. Over time, the contributions of researchers, scientists, engineers, and physicians have advanced the field of nuclear medicine, resulting in state-of-the-art equipment such as positron emission tomography (PET)/magnetic resonance imaging (MRI), positron emission tomography (PET)/computed tomography (CT), single-photon emission computed tomography (SPECT)/computed tomography (CT), and many other innovative technologies.
  • ||||||||||  Journal, PD(L)-1 Biomarker, IO biomarker:  Multiple primary tumors patient developed microsatellite stable gastric cancer after cadonilimab treatment for liver cancer: A case report. (Pubmed Central) -  Apr 28, 2025   
    Over time, the contributions of researchers, scientists, engineers, and physicians have advanced the field of nuclear medicine, resulting in state-of-the-art equipment such as positron emission tomography (PET)/magnetic resonance imaging (MRI), positron emission tomography (PET)/computed tomography (CT), single-photon emission computed tomography (SPECT)/computed tomography (CT), and many other innovative technologies. Cadonilimab not only treats microsatellite stability gastric cancer patients but can also be used for liver cancer treatment.
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
    Enrollment open, Platinum sensitive:  A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) -  Apr 26, 2025   
    P1/2,  N=50, Recruiting, 
    This report demonstrates that the combination of ICI and anti-angiogenesis therapy can induce a powerful and durable antitumor response in patients with ICI-resistant MSI-H/dMMR mCRC, which is worthy of further research. Not yet recruiting --> Recruiting
  • ||||||||||  HRS-7535 / Kailera Therapeutics
    Enrollment open:  A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity (clinicaltrials.gov) -  Apr 24, 2025   
    P3,  N=550, Recruiting, 
    Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, AiRuiKa (camrelizumab) / HLB Bio Group
    Outcomes of immunotherapy in advanced osteosarcoma patients: A systematic review and meta-analysis. () -  Apr 23, 2025 - Abstract #ASCO2025ASCO_7169;    
    The most commonly used immunotherapies included tumor-infiltrating lymphocytes (TIL) monotherapy or in combination with nivolumab (46%, n = 160) and Camrelizumab (32%, n = 111). This meta-analysis shows promising results for immunotherapy in osteosarcoma treatment and highlights the need for prospective trials with larger patient populations to understand immunotherapy outcomes in osteosarcoma better.
  • ||||||||||  Airui'en (rezvilutamide) / Jiangsu Hengrui Pharma, Baituowei (goserelin acetate sustained-release microspheres for injection) / Luye Group, goserelin acetate 3-month extended-release microspheres (LY01022) / Luye Group
    Efficacy of triplet therapy based on organoid drug sensitivity testing in lung metastatic hormone-sensitive prostate cancer. () -  Apr 23, 2025 - Abstract #ASCO2025ASCO_5716;    
    The triple regimen of goserelin acetate extended-release microspheres in combination with rezvilutamide and docetaxel demonstrated encouraging outcomes in HSPC with lung metastasis. The construction of organoid and drug sensitivity assays holds great potential in facilitating more precise screening of suitable treatment regimens for individual patients.
  • ||||||||||  Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiRuiKa (camrelizumab) / HLB Bio Group
    The combination of PD-1 inhibitor with chemotherapy  () -  Apr 23, 2025 - Abstract #ASCO2025ASCO_5484;    
    The combination of PD-1 with chemotherapy for the treatment of locally primary-recurrent of ESCC following definitive chemoradiotherapy or radiotherapy represents a safe and efficacious therapeutic strategy. This approach not only improve ARS but also ensures safety and manageable outcomes.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Real-world analysis of effectiveness in unresectable hepatocellular carcinoma patients treated with camrelizumab-based regimens. () -  Apr 23, 2025 - Abstract #ASCO2025ASCO_5469;    
    Camrelizumab-based regimens exhibited encouraging real-world effectiveness in unresectable HCC patients, achieving enhanced control of tumor progression while preserving liver function throughout the treatment. These findings provide valuable insights into the use of camrelizumab in routine clinical practice and highlight its potential as a foundational therapy for unresectable HCC within real-world patient populations.